pIC administration in the context of its use as an adjuvant has been shown to support the induction of both humoral and cellular immune responses [29], and recent studies support the use of IN vaccination with pIC to induce both nasal IgA and serum IgG to protect against homologous and heterologous infections [19], [20]. The gene discussed is CD79A; the disease is infection.